Metrion was an early participant in the Comprehensive In vitro Proarrhythmia Assay (CiPA) ion channel HTS sub-team, and also a member of the Health and Environmental Sciences Institute (HESI) cardiac committee. Working closely with HESI we contributed our expertise to help reduce data variability between screening sites and provided validation data to support efforts generating predictive in silico models. We have highly validated assays for a wide range of human ventricular ion channels, including the full CiPA panel: hERG, peak and late Nav1.5, Cav1.2, KCNQ1/KCNE1, Kir2.1 and Kv4.3 (Table 1), as well as a robust dynamic hERG assay, the data from which can be used to improve the accuracy of the FDA in silico qNet model. Screening services against HCN4 and Kv1.5, which play important roles in controlling human heart rate and atrial repolarisation, respectively, are also provided.

We provide potency assessments against each cardiac ion channel using single-point or four-point concentration-response assays using:

1. The QPatch48 automated patch-clamp platform.
2.Gold standard manual patch-clamp methodology.

The potency data derived from these high-fidelity platforms are suitable for use in in silico action potential models, a key component of the CiPA initiative.

Cardiac screening assays have been developed against hERG, NaV1.5 and CaV1.2 on the Qube, a 384 well automated patch-clamp platform. Several different assay configurations are available.

We have developed and validated a version of the challenging ‘Milnes’ dynamic hERG voltage protocol suitable for automated patch clamp. Allowing for a comprehensive analysis of larger compound numbers in this assay.

The International Council on Harmonization (ICH) S7B and E14 regulatory guidelines were introduced in 2005 to evaluate the proarrhythmic liability of new drugs. They were implemented in response to the discovery that inhibition of the rapid delayed rectifier potassium current (IKr), which is encoded by the human ether-à-go-go related gene (KV11.1), is associated with prolongation of the QT interval and the potentially deadly arrhythmia, Torsades de Pointes.

The guidelines utilise hERG inhibition and QT interval prolongation as surrogate markers of proarrhythmic liability, which are highly sensitive and have proven effective at preventing proarrhythmic drugs from reaching the market. However, these markers have low specificity, with only a modest correlation between hERG inhibition, QT prolongation and proarrhythmic liability. Therefore, to address these limitations, the Comprehensive in Vitro Proarrhythmia Assay initiative was launched by the Food and Drug Administration (FDA) in July 2013. The CiPA initiative aims to improve the accuracy and reduce the cost of predicting cardiac liability using three ‘pillars’:

These efforts more recently have resulted in the updates to the original ICH S7B/E14 guidance in the form of a Q&A document. The recommendations form this document now form the basis of regulatory requirements for IND enabling GLP studies as related to preclinical and clinical assessment of arrhythmia liability.